Fresh2 Group (FRES) Stock Price, News & Analysis

Company Overview

Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup packages, as well as technology services comprising market research, designing, coding, developing, testing, etc. In addition, the company sells genetic testing kits and skin-care products; and owns core technology platforms, as well as engages in technology development and product distribution. Further, it operates an e-commerce platform that connects food suppliers and supermarket operators and restaurant owners. The company was formerly known as AnPac Bio-Medical Science Co., Ltd. and changed its name to Fresh2 Group Limited in April 2023. The company was incorporated in 2010 and is based in New York, New York.

Key Stats

• Today's Range: $0.85 to $0.85
• 50-Day Range: $0.85 to $1.38
• 52-Week Range: $0.73 to $2.49
• Volume: N/A
• Average Volume: 33,281 shs
• Market Capitalization: $765 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FRES Stock Analysis - Frequently Asked Questions

When did Fresh2 Group's stock split?

Fresh2 Group's stock reverse split before market open on Wednesday, July 10th 2024.The 1-10 reverse split was announced on Wednesday, July 10th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Fresh2 Group IPO?

Fresh2 Group (FRES) raised $17 million in an IPO on Friday, January 10th 2020. The company issued 1,333,360 shares at a price of $12.00-$14.00 per share.

What other stocks do shareholders of Fresh2 Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fresh2 Group investors own include Amgen (AMGN), Amprius Technologies (AMPX), Axon Enterprise (AXON), PACCAR (PCAR), Arch Capital Group (ACGL), Adobe (ADBE) and Analog Devices (ADI).

Company Calendar

• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Multi-Sector Conglomerates
• Industry: Medical laboratories
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FRES
• CIK: 1786511
• Web: www.anpacbio.com
• Phone: 86-57-8205-1666
• Fax: N/A
• Employees: 75
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.75 million
• Price / Sales: 0.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 900,000
• Free Float: 663,000
• Market Cap: $765 thousand
• Optionable: Not Optionable
• Beta: 1.30